Lexicon Pharmaceuticals, INC 8-K filings

Lexicon Pharmaceuticals announced second quarter 2026 financial results, highlighting completed enrollment in its SONATA-HCM study and progress on its ZYNQUISTA NDA resubmission.

Lexicon Pharmaceuticals announced its first quarter 2026 financial results, highlighting progress in its cardiometabolic pipeline, including updates on sotagliflozin and ZYNQUISTA, alongside a strengthened financial position.

Lexicon Pharmaceuticals has entered into a $100 million loan and security agreement with Hercules Capital, providing significant financial flexibility and capital to support its pipeline and upcoming milestones.

Lexicon Pharmaceuticals reported its fourth quarter and full-year 2025 financial results, highlighting significant pipeline progress and a strengthened financial position.

Lexicon Pharmaceuticals announced the pricing of a public offering and concurrent private placement, raising approximately $94.6 million to fund research and development.

Lexicon Pharmaceuticals initiated an underwritten public offering and a concurrent private placement to fund research and development, while also providing updates on its clinical pipeline and cash position.

Lexicon Pharmaceuticals, Inc. filed an 8-K to correct an inadvertent statement in a prospectus supplement regarding an audit of internal controls, related to its ongoing $75 million at-the-market stock offering.

Lexicon Pharmaceuticals filed a prospectus supplement for an at-the-market offering of up to $75 million in common stock, though no sales have occurred yet.

Lexicon Pharmaceuticals reported increased Q3 2025 revenues and a reduced net loss, driven by licensing revenue and R&D pipeline advancements.

Lexicon Pharmaceuticals reported a significant increase in Q2 2025 revenues and a return to net income, driven by a new licensing agreement and pipeline advancements.

Lexicon Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq's minimum $1 bid price requirement, closing the matter related to its previous non-compliance.

Lexicon Pharmaceuticals, Inc. has received an additional 180-day period from Nasdaq to regain compliance with the minimum $1 bid price requirement, necessitating a transfer of its common stock to the Nasdaq Capital Market.

Lexicon Pharmaceuticals, Inc. announced that its stockholders approved significant increases in its equity incentive plan share pools and granted the Board discretion to implement a reverse stock split at a ratio between 1-for-10 and 1-for-50.

Lexicon Pharmaceuticals reports a strong start to 2025 with a focus on R&D, highlighted by an exclusive licensing agreement with Novo Nordisk and progress in clinical trials.

Lexicon Pharmaceuticals licenses its preclinical obesity drug candidate LX9851 to Novo Nordisk for a potential $960 million, while also amending its loan agreement with Oxford Finance.

Lexicon Pharmaceuticals announces positive topline results from its Phase 2b PROGRESS study of pilavapadin for diabetic peripheral neuropathic pain and reports increased revenue for 2024.

Lexicon Pharmaceuticals has received a notice from Nasdaq for failing to maintain a minimum share price of $1, putting the company at risk of delisting.

Lexicon Pharmaceuticals has appointed Scott M. Coiante as its new Senior Vice President and Chief Financial Officer, effective January 2, 2025.

Lexicon Pharmaceuticals will eliminate its commercial operations and reduce its workforce by approximately 60% after receiving a negative response from the FDA regarding its New Drug Application for ZYNQUISTA.

Lexicon Pharmaceuticals has appointed Ivan H. Cheung to its board of directors, effective December 2, 2024, while also announcing the retirement of Dr. Robert J. Lefkowitz from the board on the same date.

Lexicon Pharmaceuticals reported its Q3 2024 financial results, highlighted by a new licensing agreement with Viatris and progress in its clinical pipeline.

Lexicon Pharmaceuticals has granted Viatris exclusive rights to develop and commercialize sotagliflozin in all markets outside the US and Europe, securing an upfront payment and potential milestone payments.

Lexicon Pharmaceuticals' President and COO, Jeffrey L. Wade, will depart on September 30, 2024, with Kristen L. Alexander appointed as the new principal financial officer.

Lexicon Pharmaceuticals announced its second quarter 2024 financial results, highlighted by $1.6 million in INPEFA sales and the resubmission of the ZYNQUISTA NDA.

Lexicon Pharmaceuticals has appointed Michael Exton as its new CEO and promoted Jeffrey Wade to COO, effective July 8, 2024.

Lexicon Pharmaceuticals has amended its loan agreement with Oxford Finance, extending the interest-only period, loan maturity, and modifying financial covenants related to net sales of INPEFA and minimum cash reserves.

Lexicon Pharmaceuticals converted all outstanding preferred stock into common stock and increased the number of authorized common shares.

Lexicon Pharmaceuticals reported its Q1 2024 financial results, highlighting progress in the commercial launch of INPEFA, pipeline advancements, and a strengthened financial position.

Lexicon Pharmaceuticals' CEO, Lonnel Coats, will retire effective July 7, 2024, prompting a search for his replacement.

Lexicon Pharmaceuticals has filed a Certificate of Designations for a new Series A Convertible Preferred Stock, which will convert into common stock upon shareholder approval of an increase in authorized shares.